Wegovy: FDA-Approved Semaglutide for Chronic Weight Management

Wegovy is an FDA-approved semaglutide injection used for chronic weight management in adults with obesity or overweight and weight-related conditions. Approved on June 4, 2021, this once-weekly medication mimics the GLP-1 hormone to regulate appetite and is intended for use alongside a reduced-calorie diet and increased physical activity.

How does Wegovy work for weight management?

Wegovy is a brand-name injection containing semaglutide, which acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. According to the New England Journal of Medicine, the drug mimics the human GLP-1 hormone to help patients feel fuller and reduce overall appetite.

The medication is delivered via a once-weekly subcutaneous injection using a prefilled pen. Novo Nordisk notes that patients or caregivers can typically administer the dose at home following professional healthcare training.

Did You Know? The FDA officially approved Wegovy for chronic weight management in eligible adults on June 4, 2021.

Who is eligible for Wegovy in the United States?

FDA guidelines specify that Wegovy is for adults with a body mass index (BMI) of at least 30 kg/m2. It is also indicated for adults with a BMI of at least 27 kg/m2 who have at least one weight-related condition.

These qualifying conditions include hypertension, dyslipidemia, or type 2 diabetes. The medication must be used as an adjunct to increased physical activity and a reduced-calorie diet.

Why is this medication significant for obesity care?

The STEP clinical trial program demonstrated the drug’s efficacy. According to the New England Journal of Medicine, adults with obesity using once-weekly semaglutide plus lifestyle changes achieved significantly greater weight reduction over 68 weeks than those using a placebo.

Novo Nordisk's STEP UP Trial: A Game-Changer in Obesity Treatment

This has shifted the clinical approach in the U.S. The CDC reported on February 28, 2024, that primary care providers and obesity specialists are increasingly incorporating GLP-1 based therapies into long-term management strategies alongside nutritional counseling.

Expert Insight: Samantha Carter suggests that the shift toward GLP-1 therapies represents a transition in how the medical community views obesity—moving from a behavioral challenge to a chronic condition requiring long-term pharmacological support.

What happens next for the obesity drug market?

Novo Nordisk has reported strong global demand for semaglutide-based treatments. To address this, the company is increasing manufacturing capacity to improve supply reliability and coordinating launches in new markets.

The market is likely to remain competitive. According to the Financial Times, Wegovy competes with other GLP-1 receptor agonists, reflecting a broader industry investment in medical obesity treatment.

Future developments may include new delivery methods. While Wegovy is currently an injectable, Novo Nordisk is studying an oral semaglutide pill for obesity, though this is not yet the same product as the approved injection.

Frequently Asked Questions

Who is Wegovy for in the United States?
It is indicated for adults with obesity or overweight plus at least one weight-related condition, used alongside a reduced-calorie diet and increased physical activity.

Is Wegovy the same as semaglutide for diabetes?
No. While both contain semaglutide, the FDA states they are approved for different indications, target populations, and dosing schedules.

Is there an oral Wegovy pill available?
As of early 2026, Wegovy is only available as an injection. An oral semaglutide pill for obesity is being studied separately.

How do you feel about the integration of prescription medications into long-term weight management strategies?